Henlius Present P-III Data of HLX02 (biosimilar, trastuzumab) at ESMO

 Henlius Present P-III Data of HLX02 (biosimilar, trastuzumab) at ESMO

Henlius Present P-III Data of HLX02 (biosimilar, trastuzumab) at ESMO

Shots:

  • The P-III HLX02-BC01 study involves assessing HLX02 vs EU-sourced trastuzumab in combination with docetaxel in a 3wks. cycle for up to 1yr. in patients in a ratio (1:1) with HER2-positive recurrent/ mBC, prior not treated with systemic treatment  
  • Results:  Per ITT set, ORRwk24 (71.3% vs 71.4%); Per PP set, ORRwk24 (74.2% vs 73.2%); All subgroup analyses showed no statistically significant differences in ORR between the treatment groups in all populations, demonstrating the equivalence in efficacy
  • No difference between the two treatment groups in 2EPs, including CBR, DCR, DoR, PFS, and OS

Click here ­to­ read full press release/ article | Ref: Henlius | Image: Henlius

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post